Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study
Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study
复制标题
DOI：
10.1016/s0090-8258(02)00068-9
复制
发表时间：
2003-03-01
影响因子：
4.7
通讯作者：
Rocereto, TF
中科院分区：
文献类型：
--
作者：
Lincoln, S;Blessing, JA;Rocereto, TF
Objective.评估紫杉醇（Taxol）对既往化疗失败的持续性或复发性子宫内膜癌患者的抗肿瘤活性。确定紫杉醇在这组患者中毒性的性质和程度。Paclitazone的初始剂量为200 mg/m2，每21天一次，3小时输注，既往接受过盆腔放疗的患者为175 mg/m2。剂量调整基于血液学和非血液学的最低毒性，并通过剂量水平调整完成。剂量水平为200、175、135和110 mg/m2。患者在接受一剂紫杉醇治疗并存活3周后可评价反应。在接受任何紫杉醇治疗后，可评价其毒性。在44例可评价缓解的患者中，3例患者（6.8%）达到完全缓解，9例患者（20.5%）达到部分缓解，总缓解率为27.3%。真实缓解率的95%置信区间为15- 42.8%。紫杉醇至缓解的中位疗程数为2（范围：0.1 -4），中位缓解持续时间为4.2个月。中位总生存期为10.3个月。在48例可评价毒性的患者中，28例至少发生1次3级或4级中性粒细胞减少症，1例治疗相关死亡。在这组既往接受过治疗的患者中，有4例患者发生了3级神经毒性，其中大多数患者接受了含顺铂的化疗。几乎没有心脏毒性，48例患者中只有3例发生3级或4级胃肠道疾病。紫杉醇是一种活性药物，用于治疗既往接受过化疗的子宫内膜癌患者。(C)2003 Elsevier Science（美国）。All rights reserved.
Objective. To estimate the antitumor activity of paclitaxel (Taxol) in patients with persistent or recurrent endometrial carcinoma who have failed prior chemotherapy. To determine the nature and degree of toxicity of paclitaxel in this group of patients.Methods. Paclitaxel was administered as a 3-h infusion at an initial dose of 200 mg/m(2) every 21 days or 175 mg/m(2) for patients with prior pelvic radiation therapy. Dose modifications were based on nadir toxicity, both hematologic and nonhematologic, and were accomplished by dose level adjustments. The dose levels were 200, 175, 135, and 110 mg/m(2). Patients were evaluable for response after receiving one dose of paclitaxel and living 3 weeks. They were evaluable for toxicity after receiving any paclitaxel.Results. Of the 44 patients evaluable for response, three patients (6.8%) achieved a complete response and nine patients (20.5%) had a partial response for an overall response rate of 27.3%. The 95% confidence interval for the true response rate was 15-42.8%. The median number of courses of paclitaxel to response was 2 (range:.1-4) and the median response duration was 4.2 months. The median overall survival was 10.3 months. Of 48 patients evaluable for toxicity, 28 experienced at least one episode of grade 3 or 4 neutropenia, with one treatment-related death. There were four patients who developed grade 3 neurotoxicity in this group of previously treated patients, most of whom had received cisplatin-containing chemotherapy. There was virtually no cardiac toxicity and only 3 of 48 patients experienced grade 3 or 4 gastrointestinal symptoms.Conclusions. Paclitaxel is an active agent in the treatment of endometrial cancer in patients who have had prior chemotherapy. (C) 2003 Elsevier Science (USA). All rights reserved.